SYNTHESIS, HYDROLYTIC STABILITY AND ANTIVIRAL STUDIES OF SULFUR-BASED ANTI-INFLUENZA DRUGS

Authors

  • Maya Chochkova South-West University "Neofit Rilski" Blagoevgrad
  • Boyka Stoykova South-West University "Neofit Rilski" Blagoevgrad
  • Petranka Petrova South-West University "Neofit Rilski" Blagoevgrad
  • Haiyan Yan Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Medicinal Biotechnology
  • Nejc Petek University of Ljubljana, Faculty of Chemistry and Chemical Technology
  • Yuhuan Li Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Medicinal Biotechnology
  • Martin Štícha Charles University, Faculty of Science, Section of Chemistry
  • Lubomira Nikolaeva-Glomb The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences
  • Jurij Svete University of Ljubljana, Faculty of Chemistry and Chemical Technology

DOI:

https://doi.org/10.59957/jctm.v61.i1.2026.6

Keywords:

sulfur-containing compounds, hydrolytic stability, anti-influenza drugs, amide synthesis, influenza A viruses

Abstract

Sulfur - containing building blocks represent highly favored scaffolds in various natural or synthetically obtained pharmacologically active molecules. Their diverse functionalities, including thioether, sulfonamide, sulfoxide, and others are often linked with the possibility to inhibit microbial growth and to regulate immune responses. Nowadays, approximately 25 % of all utilized small - molecule pharmaceuticals have been approved as organosulfur drugs or are clinical candidates. Herein, inspired by the medicinal power of such compounds, a series of potential sulfur based ligands against influenza A viruses was obtained by modification of amino group of anti - influenza drugs (rimantadine, amantadine and oseltamivir) and memantine. Furthermore, the structures of novel derivatives bearing
versatile sulfur - containing acyl moieties (cysteinyl-, thienyl-) were established by spectroscopic  methods (1H NMR, 13C NMR, (ATR)umax, and HRMS). The newly synthesized amides were tested in vitro for antiviral activity against four influenza A viruses (A/Fort Monmouth/1/1947 (H1N1), A/Wuhan/359/1995 (H3N2), A/Jinnan/15/2009 (H1N1), and A/Aichi/2/68 (H3N2). Amongst the evaluated amides 1, 6, and 7 were the most active ones, inhibiting both the A/Fort Monmouth/1/1947 (H1N1) and A/Wuhan/359/1995 (H3N2) influenza virus strains, while amides 3 and 5 showed pronounced antiviral efficacy specifically against the A/Wuhan/359/1995 (H3N2) strain. Moreover, compounds 6 and 7 indicated remarkable inhibitory activity against the oseltamivir-resistant A/Jinnan/15/2009 strain.
Furthermore, the hydrolytic stability of desired amides was monitored in two model pH systems that mimic conditions in the stomach, and blood plasma, including pH 1.0, and 7.4, respectively. 

References

W.-S. Ryu, Flaviviruses, Molecular Virology of Human Pathogenic Viruses, Elsevier, 2017, 165–175.

M. He, C.-Q. He, N.-Z. Ding, Human viruses: An ever-increasing list, Virology, 604, 2025, 110445.

E.D. Kilbourne, Influenza pandemics of the 20th century, Emerg Infect Dis, 12, 2006, 9–14.

N.P.A.S. Johnson, J. Mueller, Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic, Bull Hist Med, 76, 2002, 105–115.

P.T. Hoang, Q.X.T. Luong, R.Q. Ayun, Y. Lee, T.T.B. Vo, T. Kim, S. Lee, A Novel Approach of Antiviral Drugs Targeting Viral Genomes, Microorganisms, 10, 2022, 1552.

V.M. Petrone-García, I. Castellanos-Huerta, G. Tellez-Isaias, Editorial: High-impact respiratory RNA virus diseases, Front Vet Sci, 10, 2023, 1273650.

Q.X.T. Luong, P.T. Hoang, P.T. Ho, R.Q. Ayun, T.K. Lee, S. Lee, Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA Viruses, IJMS, 26, 2025, 1481.

M.R. Sim, The COVID-19 pandemic: major risks to healthcare and other workers on the front line, Occup Environ Med, 77, 2020, 281–282.

D. Cucinotta, M. Vanelli, WHO Declares COVID-19 a Pandemic, Acta Bio Medica Atenei Parmensis, 91, 2020, 157–160.

V.J. Clemente-Suárez, E. Navarro-Jiménez, L. Moreno-Luna, M.C. Saavedra-Serrano, M. Jimenez, J.A. Simón, J.F. Tornero-Aguilera, The Impact of the COVID-19 Pandemic on Social, Health, and Economy, Sustainability, 13, 2021, 6314.

S. Martin, J. Bergmann, (Im)mobility in the Age of COVID-19, International Migration Review, 55, 2021, 660–687.

Y. Han, J. Guo, X. Li, Z. Zhong, Differences in clinical characteristics between coronavirus disease 2019 (COVID-19) and influenza: a systematic review and meta-analysis, Npj Prim. Care Respir. Med., 35, 2025, 8.

World Health Organization The burden of Influenza, 2024.

M. Golpour, H. Jalali, R. Alizadeh-Navaei, M.R. Talarposhti, T. Mousavi, A.A.N. Ghara, Co-infection of SARS‐CoV‐2 and influenza A/B among patients with COVID-19: a systematic review and meta-analysis, BMC Infect Dis, 25, 2025, 145.

R. Bekkat-Berkani, L. Romano-Mazzotti, Understanding the unique characteristics of seasonal influenza illness to improve vaccine uptake in the US, Vaccine, 36, 2018, 7276–7285.

https://data.who.int/dashboards/covid19/deaths, WHO, n.d.

World Health Organization Influenza (Seasonal)Available online: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) (Accessed 28 February 2025), n.d.

Y.-C. Liu, R.-L. Kuo, S.-R. Shih, COVID-19: The first documented coronavirus pandemic in history, Biomedical Journal, 43, 2020, 328–333.

L. Zhu, Y. Han, J. Lu, J. Tan, C. Liao, C. Guo, Q. He, Y. Qiu, H. Lu, Y. Zhou, J. Wei, D. Hu, Evaluation of Influenza Vaccine Effectiveness from 2021 to 2024: A Guangdong-Based Test-Negative Case-Control Study, Vaccines (Basel), 13, 2024, 4.

E.A. Glubokova, I.A. Leneva, N.P. Kartashova, I.N. Falynskova, R.M. Tikhov, N.Yu. Kuznetsov, Efficacy of (R)-6-Adamantane-Derivatives of 1,3-Oxazinan-2-One and Piperidine-2,4-Dione in The Treatment of Mice Infected by the A/California/04/2009 influenza Virus, Acta Naturae, 13, 2021, 116–125.

J. Han, J. Perez, A. Schafer, H. Cheng, N. Peet, L. Rong, B. Manicassamy, Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance, CMC, 25, 2019, 5115–5127.

C. Meseko, M. Sanicas, K. Asha, L. Sulaiman, B. Kumar, Antiviral options and therapeutics against influenza: history, latest developments and future prospects, Front Cell Infect Microbiol, 13, 2023, 1269344.

R. Kumari, S.D. Sharma, A. Kumar, Z. Ende, M. Mishina, Y. Wang, Z. Falls, R. Samudrala, J. Pohl, P.R. Knight, S. Sambhara, Antiviral Approaches against Influenza Virus, Clin Microbiol Rev, 36, 2023, e00040-22.

T.G. Sheu, A.M. Fry, R.J. Garten, V.M. Deyde, T. Shwe, L. Bullion, P.J. Peebles, Y. Li, A.I. Klimov, L.V. Gubareva, Dual Resistance to Adamantanes and Oseltamivir Among Seasonal Influenza A(H1N1) Viruses: 2008–2010, The Journal of Infectious Diseases, 203, 2011, 13–17.

S. Chamni, W. De-Eknamkul, Recent progress and challenges in the discovery of new neuraminidase inhibitors, Expert Opinion on Therapeutic Patents, 23, 2013, 409–423.

F.G. Hayden, N. Sugaya, N. Hirotsu, N. Lee, M.D. De Jong, A.C. Hurt, T. Ishida, H. Sekino, K. Yamada, S. Portsmouth, K. Kawaguchi, T. Shishido, M. Arai, K. Tsuchiya, T. Uehara, A. Watanabe, Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents, N Engl J Med, 379, 2018, 913–923.

J. Wang, C. Ma, J. Wang, H. Jo, B. Canturk, G. Fiorin, L.H. Pinto, R.A. Lamb, M.L. Klein, W.F. DeGrado, Discovery of Novel Dual Inhibitors of the Wild-Type and the Most Prevalent Drug-Resistant Mutant, S31N, of the M2 Proton Channel from Influenza A Virus, J. Med. Chem., 56, 2013, 2804–2812.

V.A. Shibnev, T.M. Garaev, M.P. Finogenova, E.S. Shevchenko, E.I. Burtseva, New Adamantane Derivatives Can Overcome Resistance of Influenza A(H1N1)pdm2009 and A(H3N2) Viruses to Remantadine, Bull Exp Biol Med, 153, 2012, 233–235.

K. Ulrich, U. Jakob, The role of thiols in antioxidant systems, Free Radical Biology and Medicine, 140, 2019, 14–27.

J. Yin, W. Ren, G. Yang, J. Duan, X. Huang, R. Fang, C. Li, T. Li, Y. Yin, Y. Hou, S.W. Kim, G. Wu, L ‐Cysteine metabolism and its nutritional implications, Molecular Nutrition Food Res, 60, 2016, 134–146.

M.C.D.S. Tenório, N.G. Graciliano, F.A. Moura, A.C.M.D. Oliveira, M.O.F. Goulart, N-Acetylcysteine (NAC): Impacts on Human Health, Antioxidants, 10, 2021, 967.

G.A. Hurst, P.B. Shaw, C.A. LeMaistre, Laboratory and clinical evaluation of the mucolytic properties of acetylcysteine, Am Rev Respir Dis, 96, 1967, 962–970.

J.R. Palacio, U.R. Markert, P. Martínez, Anti-inflammatory properties of N-acetylcysteine on lipopolysaccharide-activated macrophages, Inflamm. Res., 60, 2011, 695–704.

S. Dodd, O. Dean, D.L. Copolov, G.S. Malhi, M. Berk, N -acetylcysteine for antioxidant therapy: pharmacology and clinical utility, Expert Opinion on Biological Therapy, 8, 2008, 1955–1962.

A. Garozzo, G. Tempera, D. Ungheri, R. Timpanaro, A. Castro, N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection, Int J Immunopathol Pharmacol, 20, 2007, 349–354.

P. Ghezzi, D. Ungheri, Synergistic combination of N-acetylcysteine and ribavirin to protect from lethal influenza viral infection in a mouse model, Int J Immunopathol Pharmacol, 17, 2004, 99–102.

G. Roman, Thiophene-containing compounds with antimicrobial activity, Arch Pharm (Weinheim), 355, 2022, e2100462.

null Archna, S. Pathania, P.A. Chawla, Thiophene-based derivatives as anticancer agents: An overview on decade’s work, Bioorg Chem, 101, 2020, 104026.

R. Mishra, N. Kumar, N. Sachan, Thiophene and Its Analogs as Prospective Antioxidant Agents: A Retrospective Study, Mini Rev Med Chem, 22, 2022, 1420–1437.

M. Chochkova, B. Stoykova, M. Angelova, H. Sbirkova-Dimitrova, R. Rusew, Y. Li, A. Popatanasov, N. Petek, M. Štícha, B. Shivachev, Thienyl-Based Amides of M2 and Neuraminidase Inhibitors: Synthesis, Structural Characterization, and In Vitro Antiviral Activity Against Influenza a Viruses, Crystals, 15, 2025, 772.

S. Pathania, R.K. Narang, R.K. Rawal, Role of sulphur-heterocycles in medicinal chemistry: An update, European Journal of Medicinal Chemistry, 180, 2019, 486–508.

R. Listro, G. Rossino, V. Cavalloro, D. Rossi, M. Boiocchi, M.S. Robescu, T. Bavaro, S. Franchini, C. Sorbi, M. De Amici, P. Linciano, S. Collina, 1,3-Dithiolane as a Privileged Scaffold in Bioactive Derivatives: Chiral Resolution and Assignment of Absolute Configuration, IJMS, 25, 2024, 12880.

J.C. Sheehan, G.P. Hess, A New Method of Forming Peptide Bonds, J. Am. Chem. Soc., 77, 1955, 1067–1068.

D. Rajasekaran, E.A. Palombo, T. Chia Yeo, D. Lim Siok Ley, C. Lee Tu, F. Malherbe, L. Grollo, Identification of traditional medicinal plant extracts with novel anti-influenza activity, PLoS One, 8, 2013, e79293.

C. Pannecouque, D. Daelemans, E. De Clercq, Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later, Nat Protoc, 3, 2008, 427–434.

G. Hristov, Chemical Stability of New Acyclovir Analogues with Peptidomimetics, Sci. Pharm., 79, 2011, 259–264.

V.A. Shibnev, T.M. Garaev, M.P. Finogenova, E.S. Shevchenko, E.I. Burtseva, Some pathways to overcoming drug resistance of influenza a virus to adamantane derivatives, Pharm Chem J, 46, 2012, 1–5.

R. Knorr, A. Trzeciak, W. Bannwarth, D. Gillessen, New coupling reagents in peptide chemistry, Tetrahedron Letters, 30, 1989, 1927–1930.

G.R. Pettit, S.R. Taylor, Synthesis of the Marine Sponge Cycloheptapeptide Stylopeptide 11, J. Org. Chem., 61, 1996, 2322–2325.

Downloads

Published

2026-01-03

Issue

Vol. 61 No. 1 (2026)

Section

Articles

License

Copyright (c) 2026 Journal of Chemical Technology and Metallurgy

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.